JAZZ forecasts $6.18 EPS and $1.11B revenue for Q2 2026, reflecting significant year-over-year growth.
Jazz Pharmaceuticals will release its Q2 2026 earnings after markets close on August 3. Analysts expect earnings per share of $6.18, a 174.9% increase year-over-year, alongside revenue of $1.11 billion, up 5.7% from the same period last year.
The consensus estimates follow a trend of strong performance over the past two years. Prior quarters have shown steady growth, with the company exceeding expectations in recent earnings reports. The upcoming results will provide further insight into JAZZ’s financial trajectory amid ongoing market conditions.
No immediate market reaction details are available ahead of the announcement.